Magnesium deficiency is a global issue which affects approximately 68% of people. Magnesium deficiency can lead to a number of health problems including high blood pressure, heart disease, stroke, osteoporosis and arthritis. The recommended treatment up to now for absorbing these nutrients was bathing in Epsom salts, a procedure that calls for a considerable amount of time, water and electrical energy. MgSO4 has identified a market opportunity to transdermally deliver magnesium sulphate (Epsom salts) in a highly efficient and resourceful manner. The MgSpa utilises a unique water recycling system to minimise water input whilst maintaining the properties and functionality of a conventional electric shower. The MgSpa is designed for use in both commercial and residential properties and will principally be targeted toward spas and the health and wellness industry.
The technology has been developed and patented by MgSO4 and enables an Epsom salt treatment using 97% less water and 80% less energy than a standard electric shower. The technology has been validated in small scale laboratory tests however, will be further tested and validated for its technical viability. The objectives of MgSO4’s Phase 2 project are to finalise the industrial design of the MgSpa; engineering and optimisation of the MgSpa and its components, in particular the water recycling system; demonstrate and validate the technology through installations in spas and a statistical analysis of the health benefits experienced by end users; and develop a European supply and value chain. The overall objective of the project is to start full commercialisation of MgSO4’s MgSpa technology as a reliable innovation validated by the relevant clients, spas and health and wellness centres, and end-users.
